<DOC>
	<DOCNO>NCT02640833</DOCNO>
	<brief_summary>This study design assess safety , pharmacokinetics , drug-drug interaction , determine recommend Phase 2 dos co administer Duvelisib Venetoclax participant relapse refractory chronic lymphocytic leukemia ( CLL ) , small lymphocytic lymphoma , indolent aggressive non-Hodgkin lymphoma , previously receive Bcl-2 Phosphoinositide 3-kinase ( PI3K ) inhibitor . The Phase 2 portion study preliminarily evaluate efficacy , expand toxicity evaluation .</brief_summary>
	<brief_title>A Study Duvelisib Venetoclax Subjects With Relapsed Refractory Chronic Lymphocytic Leukemia , Small Lymphocytic Lymphoma , Indolent Aggressive Non-Hodgkin Lymphoma , Who Have Not Previously Received Bcl-2 PI3K Inhibitor</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<criteria>Subject must either • Relapsed refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma ( Waves 2 3 ) Subject evaluable disease require treatment opinion investigator . Subject must relapse follow refractory ≥ 1 standard treatment fludarabine base regimen ( F , FC , FR , FCR ) , alkylator ( chlorambucil , bendamustine ) base regimen , Bruton 's Tyrosine Kinase inhibitor ( Ibrutinib ) . Or • Relapsed refractory indolent NonHodgkin Lymphoma aggressive NonHodgkin Lymphoma ( Waves 1 , 2 , 3 , unless otherwise indicate ) Subject must histologically document diagnosis Follicular Lymphoma Marginal Zone Lymphoma . Subject must histologically document diagnosis Diffuse Large Bcell Lymphoma ( exclude Richter 's Transformation ) , Noncutaneous TCell Lymphoma , Mantle Cell Lymphoma ( MCL ) ( MCL Wave 3 ) Subject evaluable disease require treatment opinion investigator . Subject must relapse follow refractory ≥ 1 standard treatment RCHOP , RCVP , bendamustine , lenalidomiderituximab , fludarabinebased regimen . Subject Eastern Cooperative Oncology Group ( ECOG ) performance score less equal 2 . Subject must adequate bone marrow independent growth factor support per local laboratory reference range Screening . Subject must adequate coagulation , renal , hepatic function , per laboratory reference range Screening . NHL subject history autologous stem cell transplant ( e.g. , bone marrow ) must &gt; 6 month posttransplant ( prior first dose study drug ) must require growth factor support . Subject previously treat Bcl2 PI3K inhibitor . Subject candidate receive another secondline therapy approve usage local Health Authority . Subject appropriate stem cell transplant undergone allogeneic stem cell transplant . Subject receive follow within 14 day 5 drug halflives ( whichever shortest ) prior first dose duvelisib venetoclax , recover less Grade 2 clinically significant adverse effect ( ) /toxicity ( ) previous therapy : Any anticancer therapy include chemotherapy radiotherapy ; Investigational therapy , include target small molecule agent . Subject receive biologic agent ( e.g. , monoclonal antibody ) antineoplastic treatment within 30 day prior first dose duvelisib venetoclax . Subject receive live live attenuate vaccine within 6 week prior first dose duvelisib venetoclax . Subject receive follow within 7 day prior first dose duvelisib venetoclax : Steroid therapy antineoplastic treatment ; Strong Moderate CYP3A inhibitor ; Strong Moderate CYP3A inducer ; Chronic immunosuppressant , corticosteroid give daily dose &lt; 20 mg prednisone equivalent ITP AIHA .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Refractory Lymphoma</keyword>
	<keyword>Relapsed Leukemia</keyword>
</DOC>